fda warning compounded tirzepatide safety May 18, 2026: warns 503B compounding pharmacy for producing after shortage ended – Partnership for Safe Medicines Beware of Compounded Tirzepatide

Visual Abstract From CREDENCE Figure 6

Compounded medications are considered only when an FDA-approved therapy is not appropriate for a patients specific medical needs and a customized formulation may be clinically appropriate within an individualized care plan

An underactive thyroid reduces metabolic rate by 10 to 30 percent, depending on severity

The Journal of clinical investigation, 1993, 92(5): 2368-2376

Every lot of Retatrutide is assayed by reverse-phase HPLC-UV for purity and confirmed by LC-MS, then ships with a certificate of analysis matched to the batch number printed on the vial

Before your first injection, we want you to be fully informed about what to expect and how to manage any possible side effects